Ceralasertib + Olaparib + Durvalumab
Phase 2Active 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Gynaecological Cancers
Conditions
Gynaecological Cancers
Trial Timeline
Nov 27, 2019 → Aug 1, 2026
NCT ID
NCT04065269About Ceralasertib + Olaparib + Durvalumab
Ceralasertib + Olaparib + Durvalumab is a phase 2 stage product being developed by AstraZeneca for Gynaecological Cancers. The current trial status is active. This product is registered under clinical trial identifier NCT04065269. Target conditions include Gynaecological Cancers.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04065269 | Phase 2 | Active |
| NCT03682289 | Phase 2 | Recruiting |
Competing Products
1 competing product in Gynaecological Cancers
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SHR- A1811 | Jiangsu Hengrui Medicine | Phase 2 | 52 |